Gene: VAMP1

6843
SPAX1|SYB1|VAMP-1
vesicle associated membrane protein 1
protein-coding
12p13.31
Ensembl:ENSG00000139190 MIM:185880 Vega:OTTHUMG00000168269 UniprotKB:P23763
NG_042188.1
PubMed
0   ANCO-SNPs
CD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.983e-1 (AD)  2.744e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
NEFM0.949
EPDR10.942
NEFL0.938
NEFH0.935
ADAM230.925
NDRG30.925
INA0.925
ATP1A10.924
SH3GL20.924
GLS0.921

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LRAT-0.479
OR4F5-0.473
KLRB1-0.454
TFPI2-0.447
YES1-0.443
OR4F29-0.442
ARHGEF5-0.441
HEY2-0.438
MYL3-0.434
WWTR1-0.434

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00042Botulinum Toxin Type BBiotechDrug93384-44-2Approved|InvestigationalTarget
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VAMP1 mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of VAMP1 mRNA"19114083
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in increased expression of VAMP1 mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VAMP1 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VAMP1 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VAMP1 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VAMP1 mRNA"25510870
C0369902-amino-3,8-dimethylimidazo(4,5-f)quinoxaline"2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of VAMP1 mRNA"20816883
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of VAMP1 mRNA25458485
D000082AcetaminophenAcetaminophen results in decreased expression of VAMP1 mRNA26690555
D000082AcetaminophenAcetaminophen results in increased expression of VAMP1 mRNA21420995|2570463
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of VAMP1 gene27153756
D000452AldrinAldrin results in decreased expression of VAMP1 mRNA18579281
D000643Ammonium ChlorideAmmonium Chloride affects the expression of VAMP1 mRNA16483693
C006632arsenic trioxidearsenic trioxide results in increased expression of VAMP1 mRNA25258189
D001241AspirinAspirin results in decreased expression of VAMP1 mRNA15928584
D001280AtrazineAtrazine results in decreased expression of VAMP1 mRNA25929836
D001280AtrazineAtrazine results in increased expression of VAMP1 mRNA22378314
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of VAMP1 mRNA"19150397|2038263
C044887beta-methylcholinebeta-methylcholine affects the expression of VAMP1 mRNA21179406
C006780bisphenol Abisphenol A affects the expression of VAMP1 mRNA25181051
C096325botulinum toxin type Dbotulinum toxin type D results in increased cleavage of VAMP1 protein17666428
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of VAMP1 mRNA15336504
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of VAMP1 gene20938992
D003024ClozapineClozapine results in increased expression of VAMP1 mRNA15860345
D019327Copper SulfateCopper Sulfate results in decreased expression of VAMP1 mRNA18579281
D003471CuprizoneCuprizone results in decreased expression of VAMP1 mRNA26577399
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of VAMP1 mRNA]27941970
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of VAMP1 mRNA27392435
D000431EthanolEthanol results in decreased expression of VAMP1 mRNA20655511
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of VAMP1 gene20938992
D005557FormaldehydeFormaldehyde results in increased expression of VAMP1 mRNA20655997
D005944GlucosamineGlucosamine results in increased expression of VAMP1 mRNA17109745
D006220HaloperidolHaloperidol results in decreased expression of VAMP1 mRNA15860345
D006220HaloperidolHaloperidol results in increased expression of VAMP1 mRNA15860345
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VAMP1 mRNA25613284
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of VAMP1 mRNA27392435
C008261lead acetatelead acetate results in increased expression of VAMP1 mRNA24260418
C008261lead acetatelead acetate results in decreased expression of VAMP1 mRNA27984133
C045463leflunomideleflunomide results in decreased expression of VAMP1 mRNA28988120
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of VAMP1 gene20938992
D008767Methylmercury CompoundsMethylmercury Compounds results in decreased expression of VAMP1 mRNA26558463
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of VAMP1 mRNA"20188158
D009151Mustard GasMustard Gas results in decreased expression of VAMP1 mRNA15674843
C029938nickel sulfatenickel sulfate results in increased expression of VAMP1 mRNA22714537
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VAMP1 mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of VAMP1 mRNA26272509
D010795Phthalic AcidsPhthalic Acids results in decreased expression of VAMP1 mRNA21061450
D010936Plant ExtractsPlant Extracts results in increased expression of VAMP1 mRNA20924750
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in decreased expression of VAMP1 mRNA28903501
D011441PropylthiouracilPropylthiouracil results in decreased expression of VAMP1 mRNA24780913
C513428pyrachlostrobinpyrachlostrobin results in decreased expression of VAMP1 mRNA27029645
C096323rimabotulinumtoxinBrimabotulinumtoxinB results in increased cleavage of VAMP1 protein17666428
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of VAMP1 mRNA25895662
C017947sodium arsenitesodium arsenite results in increased expression of VAMP1 mRNA22714537
D0150852,4,5-Trichlorophenoxyacetic Acid"2,4,5-Trichlorophenoxyacetic Acid results in decreased expression of VAMP1 mRNA"18579281
D013749TetrachlorodibenzodioxinAHR protein affects the reaction [Tetrachlorodibenzodioxin results in decreased expression of VAMP1 mRNA]16891777
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VAMP1 mRNA24680724
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of VAMP1 mRNA16891777
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VAMP1 mRNA25613284
D024505TocopherolsTocopherols results in increased expression of VAMP1 mRNA17654050
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
C012589trichostatin Atrichostatin A affects the expression of VAMP1 mRNA28542535
C012589trichostatin Atrichostatin A results in decreased expression of VAMP1 mRNA24935251|2627250
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of VAMP1 mRNA"26179874
D014520UrethaneUrethane results in increased expression of VAMP1 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of VAMP1 mRNA23179753|2438349
D000069470Venlafaxine HydrochlorideVenlafaxine Hydrochloride results in decreased expression of VAMP1 mRNA25423262
C025643vinclozolinvinclozolin results in increased expression of VAMP1 mRNA23034163
D014752Vinyl ChlorideVinyl Chloride results in decreased expression of VAMP1 mRNA18579281

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI9920726  25416956  
GO ID GO Term Qualifier Evidence PubMed
GO:0035493SNARE complex assembly-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005741mitochondrial outer membrane-IEA-  
GO:0005829cytosolNOTIDA11391393  
GO:0005829cytosol-TAS-  
GO:0005887integral component of plasma membrane-TAS1976629  
GO:0009986cell surface-IEA-  
GO:0030054cell junction-IEA-  
GO:0030672synaptic vesicle membrane-TAS-  
GO:0035577azurophil granule membraneNOTIDA11391393  
GO:0035579specific granule membrane-IDA11391393  
GO:0043005neuron projection-IEA-  
GO:0070821tertiary granule membrane-IDA11391393  
KEGG ID KEGG Term
hsa04130SNARE interactions in vesicular transport
Reactome ID Reactome Term Evidence
R-HSA-1643685DiseaseTAS
R-HSA-168799Neurotoxicity of clostridium toxinsTAS
R-HSA-5250955Toxicity of botulinum toxin type D (BoNT/D)TAS
R-HSA-5250981Toxicity of botulinum toxin type F (BoNT/F)TAS
R-HSA-5250989Toxicity of botulinum toxin type G (BoNT/G)TAS
R-HSA-5339562Uptake and actions of bacterial toxinsTAS
R-HSA-5663205Infectious diseaseTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21426264Candidate pathway association study in cocaine dependence: the control of neurotransmitter release. (2012 Feb)Fernandez-Castillo NWorld J Biol Psychiatry